CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Kragujevae, Serbia

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Bio Refine for Functional Mitral Regurgitation - a Safety & Feasibility Study

    Phase

    N/A

    Span

    143 weeks

    Sponsor

    Bio Refine Ltd.

    Kragujevac

    Recruiting

  • Drug-Eluting Balloon or Drug-Eluting Stent in Acute Myocardial Infarction: A Randomized Controlled Trial

    Phase

    N/A

    Span

    210 weeks

    Sponsor

    Institute of Cardiovascular Diseases, Vojvodina

    Kragujevac

    Recruiting

  • A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

    Phase

    3

    Span

    107 weeks

    Sponsor

    Longboard Pharmaceuticals

    Kragujevac

    Recruiting

  • A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

    Phase

    3

    Span

    109 weeks

    Sponsor

    Longboard Pharmaceuticals

    Kragujevac

    Recruiting

  • Integrated Approach in Frail Older People with Atrial Fibrillation

    Controlled study, testing a structured implementation of an appropriate management of elderly AF patients with multimorbidity in clinical practice (adapting the ABC pathway and integrating the means of CGA) versus usual care; it is designed to provide reliable evidence of an active holistic integrated management approach to a common, multimorbid and 'high risk' clinical condition. AFFIRMO use a novel platform (iABC) in a cluster randomized trial design, randomizing centres to iABC versus usual care. Centres will be selected in each participating country (Bulgaria, Denmark, Italy, Romania, Serbia and Spain) under the responsibility of National Coordinators on the basis of a demonstrated interest in managing patients with AF. The 8-10 participating clusters in each country (see study size below) will be randomized in a 1:1 ratio to receive a quality-improvement intervention (iABC, experimental group) or 'usual care' practice (control group). The randomization will occur in each Country once all clusters selected in the Country have obtained IRB approval. The allocation schedule for random assignment of care models (iABC or usual care) to sites will be computer generated at the Central Coordinating Centre. The clusters in each Country will be stratified in 2 groups: Centres with or without interventional electrophysiology laboratory for AF ablation.

    Phase

    N/A

    Span

    95 weeks

    Sponsor

    Heart Care Foundation

    Kragujevac

    Recruiting

  • Volrustomig Priming Regimens Exploratory Phase II Platform Study

    This is a platform, randomized, open-label, multicenter, global study. Enrolled participants with Stage IV non-squamous non-small cell lung cancer (NSQ NSCLC) who are treatment-naïve and have not received previous treatment for advanced or metastatic disease. These participants will be randomized in a 1:1 ratio to one of the two treatment arms: Arm 1A and Arm 1B. Both arms will test a volrustomig dosing in combination with chemotherapy.

    Phase

    2

    Span

    149 weeks

    Sponsor

    AstraZeneca

    Kragujevac

    Recruiting

  • A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

    Phase

    1

    Span

    129 weeks

    Sponsor

    Dren Bio

    Kragujevac

    Recruiting

  • Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

    Phase

    3

    Span

    166 weeks

    Sponsor

    Octapharma

    Kragujevac

    Recruiting

  • Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

    Phase

    3

    Span

    239 weeks

    Sponsor

    Kartos Therapeutics, Inc.

    Kragujevac

    Recruiting

  • A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

    This multicenter, randomized, double-blind, placebo-controlled Phase 3 study is designed to compare the efficacy and safety of two dose levels of ficlatuzumab combined with cetuximab (Arm 1 or Arm 2) to a control arm of placebo plus cetuximab (Arm 3) in participants with R/M human papilloma virus (HPV)-negative HNSCC. Eligible participants must have failed prior therapy with an anti-PD-1 [programmed cell death protein 1] or PD-L1 [programmed death ligand 1] immune checkpoint inhibitor (ICI) and with platinum-based chemotherapy, administered in combination or sequentially. Failure of prior treatment may be due to progression of disease or intolerance to treatment. It is anticipated that the study will enroll approximately 410 participants across 3 arms.

    Phase

    3

    Span

    203 weeks

    Sponsor

    AVEO Pharmaceuticals, Inc.

    Kragujevac

    Recruiting

1-10 of 75
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information